| |
Pre-injury
|
Post-operation
|
|---|
| | |
3 months
|
6 months
|
9 months
|
12 months
|
|---|
|
SF-12 PCS
|
|
Group A
|
45.9 ± 8.5
|
28.2 ± 11.3
|
37.2 ± 10.8
|
39.2 ± 11.0
|
44.3 ± 11.6
|
|
Group B
|
46.2 ± 9.8
|
29.2 ± 11.3
|
38.1 ± 10.6
|
40.3 ± 9.9
|
45.0 ± 10.0
|
|
SF-12 MCS
|
|
Group A
|
59.2 ± 11.9
|
50.8 ± 11.1
|
53.7 ± 9.3
|
51.9 ± 10.6
|
54.2 ± 10.5
|
|
Group B
|
58.6 ± 10.9
|
51.7 ± 11.6
|
53.4 ± 9.5
|
52.4 ± 11.9
|
54.5 ± 10.9
|
- Group A: patients without supplementary pharmacologic treatment
- Group B: patients treated with teriparatide
- Values are shown as mean (standard deviation)
- p-values for between-group comparison were determined by Student’s t test
- Abbreviations: HHS, Harris hip score
- *Statistically significant (p < 0.05)
